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Abstract
Purpose There are currently no validated biomarkers
predicting bevacizumab treatment outcome or toxicity. We
combined biomarker data from six phase III trials of bev-
acizumab to assess whether genetic variation in vascular
endothelial growth factor-A (VEGF-A) pathway or
hypertension-related genes are associated with bev-
acizumab-induced hypertension.
Experimental design Germline DNA was available from
1,631 patients receiving bevacizumab-containing therapy
for advanced solid tumors. Overall, 194 white patients had
grade 1–4 bevacizumab-induced hypertension. In total, 236
single nucleotide polymorphisms (SNPs) located in VEGF-
A, VEGF-A receptors (FLT1 and KDR), and other genes
were selected using a SNP tagging approach and geno-
typed. A logistic regression on individual patient data was
performed after adjustment for cancer type and five other
covariates.
Results Ten SNPs were associated with bevacizumab-
induced hypertension (P B 0.05), but none surpassed the
threshold adjusted for multiple testing (P \ 0.0002). The
most significant VEGF-A pathway SNP was rs1680695 in
EGLN3 [allelic odds ratio (OR) 1.50 [95 % confidence
interval (Cl) 1.09–2.07], P = 0.012]. Two additional
SNPs, rs4444903 in EGF and rs2305949 in KDR, were
associated with hypertension (allelic OR 1.57 [95 % CI
1.17–2.11], P = 0.0025; allelic OR 0.62 [95 % CI
0.42–0.93], P = 0.020, respectively) and closely linked to
nearby functional variants. Consistent with previous
reports, rs11064560 in WNK1 was also associated with
bevacizumab-induced hypertension (OR 1.41 [95 % CI
1.04–1.92], P = 0.028).
Conclusions The genes described in this large genetic
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investigation regarding their role in mediating bev-
acizumab-induced hypertension.
Keywords Anti-angiogenesis  Bevacizumab 
Hypertension  Single nucleotide polymorphism 
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Introduction
Bevacizumab is a humanized monoclonal antibody against
vascular endothelial growth factor (VEGF)-A, a key factor
inducing the formation of blood vessels (angiogenesis) in
tumors [1]. Bevacizumab was the first anti-angiogenic
agent approved for use in the clinic. In combination with
standard chemotherapy, it is currently used for the treat-
ment of metastatic colorectal cancer (mCRC) [2–4] and
non-small cell lung cancer (NSCLC) [5]. The drug is also
approved in combination with interferon a-2a for renal cell
carcinoma (RCC) [6]. In addition, in Europe bevacizumab
is approved with standard chemotherapy for advanced
breast cancer [7, 8] and advanced ovarian cancer [9–11],
while in the United States it is approved as a single agent
for recurrent glioblastoma [12].
Treatment-related hypertension has been linked with
several anti-angiogenic therapies, including bevacizumab
[13–15] Hypertension is one of the most common side
effects of bevacizumab therapy. According to a meta-
analysis of 12,656 patients with cancer participating in
phase II/III trials of bevacizumab, the incidence of all-
grade bevacizumab-induced hypertension was 23.6 % [16];
grade 3/4 hypertension occurred in 7.9 % of patients. In
individual phase III trials, incidences of grade 3/4 hyper-
tension up to 17 % were reported with bevacizumab [7, 11,
17]. As early initiation of antihypertensive therapy may
help to maintain treatment schedules [18, 19] and reduce
complications [20, 21], identification of patients at high
risk for bevacizumab-induced hypertension could be clin-
ically valuable. Anti-angiogenic strategies are used
increasingly for prolonged periods and/or in multiple
treatment lines [4], and consequently the clinical impor-
tance of managing complications resulting from chronic
blood pressure elevation might gain increased prominence.
One widely held hypothesis for the mechanism of
angiogenesis inhibitor-associated hypertension centers on
the role of VEGF-A in nitric oxide (NO) regulation [22,
23]. NO is a potent vasodilator that plays a critical role in
blood pressure control. VEGF-A increases steady-state
endothelial NO synthase (eNOS) expression in a time- and
concentration-dependent manner [24]. In models of ische-
mic cardiomyopathy, hypotension is one of the major side
effects of VEGF-induced angiogenesis. In the clinical
setting, VEGF-A infusion causes rapid NO release and
hypotension [25]. Conversely, inhibition of VEGF-A in
animal studies reduces eNOS expression, leading to vaso-
constriction and hypertension [26]. VEGF-A blockade and
subsequent NO inhibition also appear to contribute to a
state of endothelial dysfunction [21]. VEGF-A inhibition
induces the regression of non-fenestrated microvessels—a
phenomenon known as vascular rarefraction [27].
Given the frequency of bevacizumab-induced hyper-
tension, common genetic variability may play a critical role
in patients’ susceptibility to hypertension and the severity
of this toxicity. Genetic variability in VEGF-A pathway
genes, which are important modulators of the NO pathway
and vasculature tone in general, has broadly been proposed
as a potential biomarker predictive of bevacizumab-
induced hypertension [28]. Additionally, genetic variation
in hypertension-associated genes (such as NOS3) may
increase baseline blood pressure and render patients more
susceptible to subsequent development of bevacizumab-
induced hypertension. However, investigation of potential
associations in studies requires large numbers of bev-
acizumab-treated patients. Therefore, we combined data
from six randomized phase III clinical trials of bev-
acizumab and assessed whether genetic variants in the
VEGF-A pathway or in hypertension-associated genes may
act as biomarkers for bevacizumab-induced hypertension.
Patients and methods
Study design
The genetic analyses were performed on a subset of
patients who consented to participate in a genetic substudy,
donated a blood sample from which DNA could be suc-
cessfully extracted and genotyped, and self-reported
‘white’ ethnicity (with the aim of limiting false positives by
using an ethnically homogeneous patient population).
Germline DNA was available from white patients treated in
six placebo-controlled phase III clinical trials: (1)
NO16966 (ClinicalTrials.gov identifier NCT00069095),
which tested capecitabine–oxaliplatin versus 5-fluoroura-
cil/folinic acid–oxaliplatin with or without bevacizumab as
first-line treatment for mCRC [3]; (2) AViTA (Clinical-
Trials.gov identifier NCT01214720), which tested the
addition of bevacizumab to gemcitabine and erlotinib as
first-line treatment for metastatic pancreatic cancer [29];
(3) AVAiL (ClinicalTrials.gov identifier NCT00806923),
which tested the addition of bevacizumab to standard first-
line chemotherapy (cisplatin–gemcitabine) for advanced/
recurrent non-squamous NSCLC [30, 31]; (4) AVOREN
(ClinicalTrials.gov identifier NCT00738530), which tested
the addition of bevacizumab to interferon a-2a as first-line
treatment for metastatic clear-cell RCC [6, 32]; (5)
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AVADO (ClinicalTrials.gov identifier NCT00333775),
which tested the addition of bevacizumab to docetaxel as
first-line treatment for metastatic human epidermal growth
factor receptor 2-negative breast cancer [33]; and (6)
AVAGAST (ClinicalTrials.gov identifier NCT00548548),
which tested the addition of bevacizumab to capecitabine–
cisplatin chemotherapy as first-line treatment for advanced
gastric cancer [34].
Trial protocols and genetic biomarker studies were
approved by the institutional review board at each site and
were in accordance with the Declaration of Helsinki, US
Food and Drug Administration Good Clinical Practice, and
local ethics and legal requirements. All patients included in
this study provided separate written informed consent for
genetic biomarker testing. Hypertension adverse events
were graded in all six trials according to the National
Cancer Institute Common Terminology Criteria for
Adverse Events (version 3.0) and recorded as a clinical
outcome measure. All treatment-related grade 1–4 hyper-
tension events reported at any time during the study period
for each trial were included in the analysis because
restriction to grade 3/4 hypertension provided insufficient
events for statistically meaningful analysis.
Single nucleotide polymorphism analyses
We selected single nucleotide polymorphisms (SNPs) in
the following genes involved in the VEGF-A pathway:
VEGF-A, the VEGF-A homologs (placental growth factor
[PLGF], VEGF-B, VEGF-C, and VEGF-D [also known as
c-fos-induced growth factor or FIGF]), VEGF receptor-1
(VEGFR-1 or FLT1), VEGF receptor-2 (VEGFR-2 or
KDR), VEGF receptor-3 (VEGFR-3 or FLT4), regulators of
hypoxia (hypoxia-inducible factor 1a [HIF1A], HIF-2a
[EPAS1], factor inhibiting HIF-1a [FIH1], and von Hip-
pel–Lindau tumor suppressor [VHL]), and the oxygen
sensors (prolyl hydroxylase domain-containing protein 1
[EGLN2], 2 [EGLN1], and 3 [EGLN3]). Overall, we
selected 211 tagging SNPs in these genes, as well as 9
SNPs previously correlated with bevacizumab outcome
[35]. A detailed description of how SNPs were selected has
been published previously [36, 37]. Finally, we also
included 16 SNPs known to increase susceptibility to
hypertension and thrombosis [38–41]. Overall, 236 SNPs
were selected for genotyping.
Peripheral blood was sampled in K2EDTA Vacutainer
tubes (BD, Franklin Lakes, New Jersey), and germline
DNA was extracted from the precipitated leukocyte cell
fraction. Genotyping for a subset of SNPs was carried out
in a blinded manner at the Roche Translational Research
Sciences Genetics Laboratories (Basel, Switzerland) using
allele-specific polymerase chain reaction amplification,
Sanger sequencing, and fragment-analysis platforms
(AVAiL, AViTA, AVOREN, AVADO, NO16966, and
AVAGAST). Genotyping for the majority of SNPs was
done at the Vesalius Research Center, Leuven, Belgium,
with MassARRAY iPLEX Gold (Sequenom, San Diego,
California) as described previously [42]. Overall, 222 SNPs
(94 %) were successfully genotyped in at least two studies.
Of these 222 SNPs, five occurred at a frequency of less
than 0.1 in the overall study population and were therefore
excluded.
Statistical methods
We assessed Hardy–Weinberg equilibrium in white patients
for the 217 SNPs included in this analysis using a standard
v2 test with one degree of freedom. We detected seven
markers with P \ 0.0002; however, they were not excluded
because patients were treated in various multicenter trials
involving numerous countries. Instead, homogeneity of
allele frequencies across trials was assessed using a v2 test
of homogeneity of proportions. Seven of the 217 markers
showed significant departure from homogeneity
(P \ 0.0002) and were excluded from association analyses.
For the remaining 210 markers (Supplementary Tables 1
and 2), a meta-analysis of individual patient data was per-
formed, after adjustment for cancer type and the following
covariates: geographic region, study, study dose, chemo-
therapy backbone, age, and sex. Candidate markers were
tested for association with hypertension using multiple
logistic regression while correcting for these covariates.
Markers that were nominally associated (P B 0.05) with
bevacizumab-induced hypertension in white patients were
also tested for association with progression-free survival
(PFS), overall survival (OS), and best overall response
according to Response Evaluation Criteria in Solid Tumors
using Cox proportional hazards regression or multiple
logistic regression, as appropriate, while adjusting for rel-
evant covariates. To assess linkage disequilibrium, the Le-
wontin’s D0 statistic was calculated using the Haploview
software version 4.2 [43].
Results
Patient population
Overall, 1,631 patients in the six trials consented to par-
ticipate in the genetic biomarker substudy. Of these,
approximately equal numbers received bevacizumab with
standard therapy (n = 807) or placebo with standard
therapy (n = 824). The distribution of patients across the
six trials and their baseline characteristics are summarized
in Table 1. With the exception of AViTA and AVAGAST,
all trials met their primary objective. Overall, no
Angiogenesis (2014) 17:685–694 687
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substantial differences in terms of PFS or OS were noted
between each genetic substudy and the corresponding
clinical studies. Hypertension was reported in 143 (18 %)
of 807 bevacizumab-treated patients and 51 (6 %) of 824
placebo-treated patients. Across individual studies, the
incidences of hypertension (irrespective of treatment
administered) ranged from 8 % in AVAGAST and
NO16966 to 21 % in AVAiL (Table 2).
VEGF-A pathway SNPs and bevacizumab-induced
hypertension
Of the 15 VEGF-A pathway genes, six SNPs were nomi-
nally (P B 0.05) associated with bevacizumab-induced
hypertension in white patients (Table 3), but none of these
surpassed the threshold for multiple testing (P \ 0.0002).
The strongest association was for rs1680695 in EGLN3,
with an allelic odds ratio (OR) of 1.50 (95 % confidence
interval [CI], 1.09–2.07; P = 0.012; Table 3; Fig. 1a).
Specifically, 14 (20 %) of 70 GG carriers treated with
bevacizumab developed hypertension versus 58 (21 %) of
281 TG carriers and 34 (12 %) of 276 TT carriers (Fig. 2a).
In the placebo arm, 10, 7, and 6 %, respectively, developed
hypertension.
The SNP with the second strongest association was
rs2305949 in KDR (OR 0.62; 95 % CI 0.42–0.93;
P = 0.020; Table 3; Fig. 1b). In patients treated with
bevacizumab, the incidence of hypertension was highest in
CC genotype carriers (81 [19 %] of 418 CC carriers vs. 29
[14 %] of 212 CT carriers and 3 [10 %] of 31 TT carriers;
Fig. 2b). In the placebo arm, corresponding incidences
were 5, 9 and 12 %, respectively. Intriguingly, this marker
is in linkage disequilibrium with the non-synonymous
variant rs2305948 (valine to isoleucine) occurring at
position 297 of KDR (D0 = 1), suggesting that this change
may functionally affect VEGF-A pathway signaling.
Hypertension-specific SNPs and bevacizumab-induced
hypertension
Of the selected markers outside the VEGF-A pathway, four
SNPs were nominally (P B 0.05) associated with
Table 1 Summary of demographic and recruitment data
AVAiL AVOREN AViTA AVADO NO16966 AVAGAST All
Cancer type NSCLC Renal Pancreatic Breast Colorectal Gastric
Recruitment period Feb 2005–
Aug 2006
Jun 2004–
Oct 2005
Jul 2005–
Sep 2006
Mar 2006–
Apr 2007
Feb 2004–
Feb 2005
Sep 2007–
Dec 2008
Patients participating
in the clinical study (n)
1,043 649 607 736 1,400 774 5,209
Patients consenting to the
genetic substudy (%)
119 108 160 348 610 286 1,631
Bevacizumab [n (%)] 83 (70) 59 (55) 79 (49) 238 (68) 210 (34) 138 (48) 807 (49)
Placebo [n (%)] 36 (30) 49 (45) 81 (51) 110 (32) 400 (66) 148 (52) 824 (51)
Male (%) 71 72 64 0 61 66 50
Mean age [years (SD)] 57.4 (9.9) 59.7 (10.6) 61.6 (9.6) 54.7 (10.8) 59.6 (11.5) 57.2 (11.3) 58.2 (11.2)
White (%) 92 99 95 96 85 63 86
NSCLC non-small cell lung cancer, SD standard deviation
Table 2 Summary of clinical outcomes in bevacizumab-treated arms and incidences of hypertension
AVAiLa AVOREN AVITA AVADOa NO16966 AVAGAST All
Cancer type NSCLC Renal Pancreatic Breast Colorectal Gastric
Median OS in genetic substudy, months 13.9 33.2 7.0 28.7 20.9 9.3 17.1
Censored OS in the genetic substudy (%) 36 47 9 37 19 29 27
Median PFS in genetic substudy, months 6.5 13.6 4.9 8.4 8.8 5.5 7.9
Censored PFS in genetic substudy (%) 3 11 4 7 4 14 7
Hypertension in the bevacizumab arm [n (%)] 21 (25) 17 (29) 14 (18) 41 (17) 34 (16) 16 (12) 143 (18)
Hypertension in the placebo arm [n (%)] 4 (11) 5 (10) 7 (9) 13 (12) 15 (4) 7 (5) 51 (6)
Hypertension in both treatment arms [n (%)] 25 (21) 22 (20) 21 (13) 54 (16) 49 (8) 23 (8) 194 (12)
NSCLC non-small cell lung cancer, OS overall survival, PFS progression-free survival
a Bevacizumab 15 mg/kg arm only
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bevacizumab-induced hypertension (Table 4), but none of
these surpassed the threshold for multiple testing
(P \ 0.0002). The SNP showing the strongest association
was rs4444903 in EGF (OR 1.57; 95 % CI 1.17–2.11;
P = 0.0025; Fig. 1c). At the genotype level, the mutant
G-allele of rs4444903 was associated with bevacizumab-
induced hypertension. In bevacizumab-treated patients,
hypertension was reported in 18 (8 %) of 232 AA carriers
versus 76 (24 %) of 321 AG carriers and 21 (16 %) of 130
GG carriers (Fig. 2c). Corresponding values in placebo-
treated patients were 5, 7, and 6 %, respectively. The
rs4444903 is closely linked to rs2237051, which involves
an amino acid change (methionine to isoleucine) at position
708 of EGF, suggesting that this change may functionally
affect EGF activity and thereby contribute to hypertension.
Remarkably, another marker in EGF (rs9992755), which is
48 kbp away from rs4444903, was also associated with
hypertension (P = 0.014; Table 4). Both markers are in
linkage disequilibrium with the rs2237051 non-synony-
mous change (D0 = 0.92 for rs4444903; D0 = 0.87 for
rs9992755).
One additional SNP in WNK1, rs11064560, was asso-
ciated with bevacizumab-induced hypertension
(P = 0.028). The allelic OR was 1.41 (95 % CI 1.04–1.92;
P = 0.028; Figs. 1d, 2d).
Effect of hypertension-associated SNPs on efficacy
endpoints
Finally, we assessed whether SNPs that correlated signifi-
cantly with bevacizumab-induced hypertension were also
associated with treatment efficacy (best overall response,
PFS, or OS). We identified one SNP in which the allele
associated with hypertension also correlated with improved
treatment response: the mutant G-allele of rs1680695 in
EGLN3 exhibited an improved best overall response
compared with the wild-type T-allele (allelic OR 1.39;
95 % CI 1.08–1.80; P = 0.011). However, no significant
effect of rs1680695 was observed for PFS or OS in white
patients treated with bevacizumab (PFS: allelic OR 0.89
[95 % CI 0.79–1.00], P = 0.055; OS: allelic OR 0.90
[95 % CI 0.79–1.04], P = 0.16). None of the other nine
SNPs associated with bevacizumab-induced hypertension
at P B 0.05 was associated significantly with either PFS or
OS in the meta-analysis of all six studies (data not shown).
Discussion
In this large pooled analysis, several genetic variants in
the VEGF-A pathway or in other genes linked to
Table 3 VEGF-A pathway SNPs with P B 0.05 for association with hypertension
Marker Chr Base paira MAF HWE
P value
N OR 95 % CI P value Gene
rs1680695 14 34,408,083 0.35 0.64 627 1.50 1.09–2.07 0.012 EGLN3
rs2305949 4 55,980,456 0.21 0.26 661 0.62 0.42–0.93 0.020 KDR
rs4953340 2 46,548,064 0.36 0.52 612 1.44 1.05–1.96 0.023 EPAS1
rs2034327 2 46,549,040 0.49 0.82 447 0.68 0.47–0.98 0.037 EPAS1
rs111458691 13 29,069,942 0.03 0.51 656 0.12 0.02–0.91 0.041 FLT1
rs1130379 5 180,039,606 0.08 0.01 557 1.72 1.00–2.95 0.050 FLT4
Chr chromosome, CI confidence interval, HWE Hardy–Weinberg equilibrium, MAF minor allele frequency, OR odds ratio, SNP single
nucleotide polymorphism
a Base-pair positions are calculated based on reference genome hg19
Table 4 Hypertension SNPs with P B 0.05 for association with bevacizumab-induced hypertension
Marker Chr Base paira MAF HWE P value N OR 95 % CI P value Gene
rs4444903 4 110,834,110 0.42 0.46 683 1.57 1.17–2.11 0.0025 EGF
rs9992755 4 110,882,590 0.36 0.29 658 1.45 1.08–1.96 0.014 EGF
rs1937506 13 68,035,371 0.25 0.52 644 1.53 1.09–2.15 0.015 -b
rs11064560 12 943,953 0.33 0.04 689 1.41 1.04–1.92 0.028 WNK1
Chr chromosome, CI confidence interval, HWE Hardy–Weinberg equilibrium, MAF minor allele frequency, OR odds ratio, SNP single
nucleotide polymorphism
a Base-pair positions are calculated based on reference genome hg19
b The rs1937506 SNP is located in a gene desert and its function is unknown. It is located 230 kbp upstream of PCDH9
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(a)
(b)
(c)
(d)
Fig. 1 Forest plot showing
association of bevacizumab-
induced hypertension with
single nucleotide
polymorphisms: a EGLN3
rs1680695, b KDR rs2305949,
c EGF rs4444903, and d WNK1
rs11064560. Logarithmic ORs
were calculated. Heterogeneity
was assessed by I-square and
tau-square values and a P value
for heterogeneity was
calculated. The gray blocks
represent the ORs in the
separate study populations. The
vertical dotted black line
represents the OR after meta-
analysis. The horizontal lines
are 95 % CIs. W(fixed)
indicates the weight of each
individual study. The ORs in
these forest plots differ slightly
from those in Tables 3 and 4
because ORs in the forest plot
are calculated using a fixed-
effects meta-analysis of
summary statistics, whereas the
ORs in Tables 3 and 4 are
derived from a pooled meta-
analysis of individual patient
data (our main analysis
approach). Abbreviations: CI
confidence interval, OR odds
ratio
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hypertension were associated with bevacizumab-induced
hypertension. None of these associations was significant,
however, after correction for multiple testing. Therefore
these findings would require replication in additional
studies and functional validation that affected genes are
involved in hypertension before these variants can be
considered as predictors of bevacizumab-induced
hypertension.
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Fig. 2 Bar plot showing frequency of hypertension in bevacizumab- and placebo- treated patients stratified for single nucleotide
polymorphisms: a EGLN3 rs1680695, b KDR rs2305949, c EGF rs4444903, and d WNK1 rs11064560
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For one of the variants, rs11064560 in WNK1, biological
evidence supporting the observed association in a much
smaller cohort is already available. Frey et al. observed a
predictive association between two SNPs in WNK1
(rs11064560 and rs2158501) and development of bev-
acizumab-induced hypertension in 28 patients with cancer
[44]. The WNK1 gene encodes a serine-threonine kinase
that contributes to blood pressure homeostasis through
regulation of the sodium chloride co-transporter in the
distal convoluted tubule [45]. Mutations in WNK1 also
cause Gordon’s syndrome, a rare Mendelian disorder
characterized by hypertension and hyperkalemia [46]. In
non-bevacizumab-treated populations, WNK1 polymor-
phisms were associated with hypertension in a large fam-
ily-based sample of white patients [47], and with
ambulatory blood pressure and response to thiazide
diuretics in African American and white cohorts [48].
Intriguingly, rs11064560 is in linkage disequilibrium with
one of the SNPs identified in these studies, rs765250
(D0 = 1.00). The rare allele of rs11064560, which corre-
lated with bevacizumab-induced hypertension in the pres-
ent study, is linked with the rs765250 G-allele that
correlates with increased blood pressure. Thus the observed
association with bevacizumab-induced hypertension is
biologically plausible.
The rs2305949 SNP in KDR was associated with bev-
acizumab-induced hypertension in our study. The KDR
gene contains a SNP in exon 7 (rs2305948; C/T) that
results in a non-synonymous amino acid change at residue
297 in the third immunoglobulin-like domain. HEK293
cells transfected with a plasmid construct containing the
rs2305948 TT genotype displayed a significantly lower
VEGF-A binding affinity to KDR than did wild-type CC
genotypes [49]. Likewise, we observed that human
umbilical vein endothelial cells carrying rs2305948 TT
genotypes proliferated significantly less than CC genotypes
when exposed to recombinant VEGF-A, thereby corrobo-
rating these reports (unpublished observations). Of note,
rs2305949 is in strong linkage with rs2305948 (D0 = 1),
suggesting that corresponding rs2305949 TT genotypes are
also characterized by reduced VEGF-A/KDR interaction.
This altered interaction might render the vasculature more
susceptible to vascular rarefraction and concomitant
hypertension.
We also observed that rs1680695 in EGLN3 was asso-
ciated with bevacizumab-induced hypertension and
improved overall response in our meta-analysis of six tri-
als. This indicates that carriers of the mutant G-allele may
have an increased risk for hypertension but also a higher
chance of a partial or complete response to bevacizumab.
How EGLN3 could contribute to bevacizumab-induced
hypertension at the functional level is, however, not
known. Another SNP involving an A to G mutation at
position 61 of the 50 untranslated region of EGF
(rs4444903), which results in higher epidermal growth
factor levels in GG-genotype carriers [50], was also asso-
ciated with bevacizumab-induced hypertension in our
study. This observation is noteworthy as the epidermal
growth factor receptor (EGFR) may contribute to the
development of hypertension by regulating vascular tone
and renal sodium handling [51]. Synthetic EGFR inhibitors
also reduce blood pressure in some experimental models of
hypertension and have been suggested as a novel target for
antihypertensive therapy [52].
The biological effects of the other SNPs that were
associated with bevacizumab-induced hypertension at
P B 0.05 are still unknown. Although our findings for
each of these SNPs might be relevant, additional
genetic and functional studies are needed to confirm
their association, especially since blood pressure can be
influenced by numerous environmental or clinical fac-
tors, thereby increasing the likelihood of detecting
spurious associations. It should be noted, however, that
to our knowledge the current study already represents
by far the largest dataset of patients with bevacizumab-
induced hypertension. Nevertheless, in the future, we
anticipate investigating additional phase III clinical tri-
als from the bevacizumab biomarker program—one of
the largest biomarker programs in oncology—to
increase further the number of patients assessed.
Importantly, if the identified SNPs are replicated, they
may be used to aid the selection of patients amenable
to bevacizumab treatment. The potential clinical benefit
of these SNPs is their ability to stratify patients into
risk groups for developing hypertension before admin-
istration of the drug. Patients in the highest risk group
could be monitored particularly closely for changes in
blood pressure throughout treatment, allowing hyper-
tension to be detected and treated without delay, or
could possibly even allow selection of patients for
prophylactic antihypertensive therapy.
In conclusion, this study represents a large genetic
analysis of bevacizumab-induced hypertension using
pooled datasets. Four markers, rs1680695 in EGLN3,
rs2305949 in VEGFR-2, rs4444903 in EGF, and
rs11064560 in WNK1, showed an association with hyper-
tension. Additional studies are now warranted before con-
sidering the potential role for any of these SNPs in
predicting the safety profile of bevacizumab.
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